Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD) (RenVas)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01380717|
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : February 27, 2014
Patients with reduced kidney function have a higher risk of heart disease and death. Studies have shown that blood vessels in patients with hypertension change with a decrease of lumen size and growth of the vessel wall. By treating patients with antihypertensive certain medication vessel lumen and walls normalize. Treating hypertension in patients with chronic kidney disease slows the progression of kidney function loss.
The aim is to compare different degrees of antihypertensive medication in patients with chronic kidney disease and hypertension will slow the progression of kidney loss.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Insufficiency Hypertension Vasodilation||Drug: Beta-blocker, ACE-inhibitor Drug: Calcium Channel Blockers, ACE-Inhibitor||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||83 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Role of Renal and Peripheral Vascular Resistance in Chronic Kidney Disease|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
Active Comparator: Standard treatment
Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
Drug: Beta-blocker, ACE-inhibitor
Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
Active Comparator: Intensive vasodilation
Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
Drug: Calcium Channel Blockers, ACE-Inhibitor
Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
- Change in glomerular filtration rate between the two treatment arms. [ Time Frame: Measured at baseline and after 18 months of treatment ]
- Changes in glomerular filtration rate stratified after changes in pulse wave velocity, renal vascular resistance and forearm minimal resistance at baseline and after 18 months of treatment. [ Time Frame: 18 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380717
|Department of Renal Medicine, Aarhus University Hospital, Skejby|
|Aarhus N, Denmark, 8200|
|Principal Investigator:||Niels Henrik Buus, DrMedSc||Department og Renal Medicine, Aarhus University Hospital, Skejby|